ZLDAF Stock - Zelira Therapeutics Limited
Unlock GoAI Insights for ZLDAF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $656 | $94,952 | $301,121 | $1.54M | $663,316 |
| Gross Profit | $-802,945 | $10,284 | $-3,216,063 | $-5,716,013 | $-39,161 |
| Gross Margin | -122400.2% | 10.8% | -1068.0% | -371.0% | -5.9% |
| Operating Income | $-3,952,189 | $-5,938,230 | $-6,502,127 | $-13,414,940 | $-9,652,120 |
| Net Income | $-3,627,872 | $-36,568,904 | $-5,573,007 | $-11,945,303 | $-8,549,079 |
| Net Margin | -553029.3% | -38513.0% | -1850.8% | -775.4% | -1288.8% |
| EPS | $-0.32 | $-3.22 | $-0.55 | $-1.49 | $-1.29 |
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialisation of cannabinoid-based medicines for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company also provides OTC products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as ITURA, an advanced relief cream formula that targets multi-symptoms, such as numbness and tingling, muscle cramps, insensitivities, and pain associated with Peripheral Artery Disease and diabetes. Zelira Therapeutics has strategic partnerships with Curtin University; the Telethon Kids Institute; the University of Western Australia; St. Vincent's Hospital; and the Children's Hospital of Philadelphia. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is headquartered in Perth, Australia.
Visit WebsiteEarnings History & Surprises
ZLDAFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 24, 2026 | — | — | — | — |
Q3 2025 | Aug 26, 2025 | — | $-0.07 | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Oct 29, 2024 | — | $-0.14 | — | — |
Q2 2024 | Apr 29, 2024 | — | $-2.05 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.14 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.23 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.48 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.52 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.55 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.44 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.59 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.42 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.24 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.37 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.20 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.09 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.21 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-2.24 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-2.19 | — | — |
Latest News
Frequently Asked Questions about ZLDAF
What is ZLDAF's current stock price?
What is the analyst price target for ZLDAF?
What sector is Zelira Therapeutics Limited in?
What is ZLDAF's market cap?
Does ZLDAF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ZLDAF for comparison